Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 5;131(23):2808–2816. doi: 10.4103/0366-6999.246072

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2018 Chinese Medical Journal

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

PMC Copyright notice

The impact of MRD postchemotherapy on clinical outcomes in MSDT. Patients with positive MRD after the first chemotherapy had higher CIR (32.3 ± 9.7% vs. 7.7 ± 3.1%, P = 0.055, χ² = 3.661) (a), lower LFS (67.7 ± 6.1% vs. 92.3 ± 9.8%, P = 0.046, χ² = 3.680) (b), and OS (67.7 ± 6.1% vs. 92.3 ± 9.8%, P = 0.046, χ² = 3.680) (c) than those without MRD. Patients with positive MRD after the second chemotherapy had higher CIR (57.1 ± 3.6% vs. 12.5 ± 2.7%, P = 0.003, χ² = 8.759) (d), lower LFS (42.9 ± 6.3% vs. 87.5 ± 8.7%, P = 0.002, χ² = 9.803) (e), and OS (42.9 ± 6.3% vs. 87.5 ± 8.7%, P = 0.002, χ² = 9.803) (f) than those without MRD. MRD: Minimal residual disease; MSDT: Matched sibling donor transplantation; CIR: Cumulative incidence of relapse; LFS: Leukemia-free survival; OS: Overall survival.